^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Repatha (evolocumab) (PCSK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PCSK9 inhibitor evolocumab to increase anticancer activities and reduce cardiotoxicity during doxorubicin and trastuzumab, as sequential treatment, through MyD88/NF-kB/mTORC1 pathways
Published date:
05/19/2021
Excerpt:
In human HER2+ breast cancer cells, co-exposure of Evolocumab with doxorubicin and trastuzumab increased significantly cell apoptosis and necrosis through the involvement of key cytokines involved in chemoresistence.
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.1200/JCO.2021.39.15_suppl.e15039